CytoSorbents Q1 revenue rises

Cytosorbents

13/05/2026 21:09

Overview

U.S. blood purification device maker's Q1 revenue grew 2% yr/yr

Adjusted net loss and adjusted EBITDA loss for Q1 both narrowed from prior year

Revenue growth driven by direct sales outside Germany; distributor sales flat due to Middle East delays

Outlook

CytoSorbents aims to achieve operating cash flow breakeven in the second half of 2026

Company expects distributor sales in Middle East to improve as geopolitical instability stabilizes

CytoSorbents plans to submit new DrugSorb-ATR FDA application in late 2026 or early 2027

Result Drivers

DIRECT SALES GROWTH - 13% growth in direct sales outside Germany drove overall revenue increase, per CEO Dr. Phillip Chan

GERMANY SALES TEAM RESTRUCTURING - German sales were slightly below last year but attributed to a smaller, more focused team under new leadership, per company

MIDDLE EAST DELAYS - Distributor sales were flat as progress in some territories was offset by delayed orders in the Middle East due to geopolitical and economic instability, per company

Company press release: ID:nPnJw0Ga

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$8.9 mln
$9.36 mln (2 Analysts)
Q1 EPS
-$0.08


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cytosorbents Corp is $5.00, about 753.4% above its May 12 closing price of $0.59

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)